Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of oxytocin in patients with borderline personality disorder
2010-020956-69Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in borderline personality disorder (BPD) and major depressive disorder (MDD) comparing Oxytocin nasal spray plus standard inpatient DBT with Placebo nasal spray plus standard inpatient DBT (2 arms). Primary endpoint: Borderline symptom severity. Started Oct 2010; status: completed.
02
Drugs
oxytocin
03
Conditions
borderline personality disorder (BPD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-020956-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020956-69.